Non-Alcoholic Steatohepatitis - Pipeline Review, H2 2016

  • ID: 3821696
  • Drug Pipelines
  • 342 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Akarna Therapeutics Ltd.
  • AlbireoPharma
  • Amunix Operating Inc.
  • AstraZeneca Plc
  • BiOrion Technologies B.V.
  • Bird Rock Bio, Inc.
  • MORE
Non-Alcoholic Steatohepatitis - Pipeline Review, H2 2016

Summary

‘Non-Alcoholic Steatohepatitis - Pipeline Review, H2 2016’, provides an overview of the Non-Alcoholic Steatohepatitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Non-Alcoholic Steatohepatitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Non-Alcoholic Steatohepatitis and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Non-Alcoholic Steatohepatitis
- The report reviews pipeline therapeutics for Non-Alcoholic Steatohepatitis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Non-Alcoholic Steatohepatitis therapeutics and enlists all their major and minor projects
- The report assesses Non-Alcoholic Steatohepatitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Non-Alcoholic Steatohepatitis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Non-Alcoholic Steatohepatitis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Non-Alcoholic Steatohepatitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Akarna Therapeutics Ltd.
  • AlbireoPharma
  • Amunix Operating Inc.
  • AstraZeneca Plc
  • BiOrion Technologies B.V.
  • Bird Rock Bio, Inc.
  • MORE
List of Figures

Introduction

Report Coverage

Non-Alcoholic Steatohepatitis Overview

Therapeutics Development

Pipeline Products for Non-Alcoholic Steatohepatitis - Overview

Pipeline Products for Non-Alcoholic Steatohepatitis - Comparative Analysis

Non-Alcoholic Steatohepatitis - Therapeutics under Development by Companies

Non-Alcoholic Steatohepatitis - Therapeutics under Investigation by Universities/Institutes

Non-Alcoholic Steatohepatitis - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Unknown Stage Products

Non-Alcoholic Steatohepatitis - Products under Development by Companies

Non-Alcoholic Steatohepatitis - Products under Investigation by Universities/Institutes

Non-Alcoholic Steatohepatitis - Companies Involved in Therapeutics Development

Akarna Therapeutics Ltd.

AlbireoPharma

Alnylam Pharmaceuticals, Inc.

Amunix Operating Inc.

Aquinox Pharmaceuticals Inc.

Arisaph Pharmaceuticals, Inc.

AstraZeneca Plc

BiOrion Technologies B.V.

Bird Rock Bio, Inc.

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

Can-Fite BioPharma Ltd.

Cardax Pharmaceuticals, Inc.

Catabasis Pharmaceuticals, Inc.

Cerenis Therapeutics Holding SA

Conatus Pharmaceuticals Inc.

Connexios Life Sciences Pvt. Ltd.

Daiichi Sankyo Company, Limited

DURECT Corporation

Dynavax Technologies Corporation

Eli Lilly and Company

Enanta Pharmaceuticals, Inc.

Exicure, Inc.

Galectin Therapeutics, Inc.

Galmed Pharmaceuticals Ltd.

Genextra S.p.a.

Genfit SA

GenKyoTex S.A.

Gilead Sciences, Inc.

GRI Bio, Inc.

iCo Therapeutics Inc.

Immuron Limited

Inventiva

Ionis Pharmaceuticals, Inc.

Ixchel Pharma, LLC

Jenrin Discovery, Inc.

Kissei Pharmaceutical Co., Ltd.

Kyorin Pharmaceutical Co., Ltd.

Matinas BioPharma Holdings, Inc.

Merck & Co., Inc.

Mitochon Pharmaceuticals, Inc.

Naia Limited

NGM Biopharmaceuticals, Inc.

Nimbus Therapeutics, LLC

Nippon Chemiphar Co., Ltd.

Nitto Denko Corporation

Novartis AG

NovaTarg Therapeutics, Inc

Nuevolution AB

Pharmaxis Limited

Promethera Biosciences S.A.

ProMetic Life Sciences Inc.

Protalix BioTherapeutics, Inc.

Saje Pharma, LLC

Shire Plc

Stelic Institute & Co., Inc.

Sucampo Pharmaceuticals, Inc.

TaiwanJ Pharmaceuticals Co., Ltd.

Teva Pharmaceutical Industries Ltd.

Therapix Biosciences Ltd

Tobira Therapeutics, Inc.

Vascular Biogenics Ltd.

Verlyx Pharma Inc.

Viking Therapeutics, Inc.

Virobay Inc.

Zafgen Inc.

Zydus Cadila Healthcare Limited

Non-Alcoholic Steatohepatitis - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Combination Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

(leucine + metformin hydrochloride + sildenafil citrate) - Drug Profile

(leucine + PDE5 Inhibitor) - Drug Profile

A-4250 - Drug Profile

AC-261066 - Drug Profile

AM-0010 - Drug Profile

AMX-342 - Drug Profile

Antisense Oligonucleotides for Non-Alcoholic Steatohepatitis - Drug Profile

AQX-1125 - Drug Profile

Aramchol - Drug Profile

ARI-3037MO - Drug Profile

AZD-4076 - Drug Profile

bertilimumab - Drug Profile

BMS-986036 - Drug Profile

BMS-986171 - Drug Profile

BOT-191 - Drug Profile

CAT-2000 Series - Drug Profile

CAT-2054 - Drug Profile

CDX-085 - Drug Profile

cenicriviroc mesylate - Drug Profile

CER-209 - Drug Profile

CF-102 - Drug Profile

CNX-014 - Drug Profile

CNX-023 - Drug Profile

CNX-024 - Drug Profile

CNX-025 - Drug Profile

DRX-065 - Drug Profile

DUR-928 - Drug Profile

DV-1179 - Drug Profile

EDP-305 - Drug Profile

elafibranor - Drug Profile

emricasan - Drug Profile

etanercept biosimilar - Drug Profile

evogliptin - Drug Profile

GKT-831 - Drug Profile

GRI-0621 - Drug Profile

GRMD-02 - Drug Profile

GS-9674 - Drug Profile

HepaStem - Drug Profile

IMM-124E - Drug Profile

IONIS-DGAT2Rx - Drug Profile

IVA-337 - Drug Profile

IXC-303 - Drug Profile

IXC-305 - Drug Profile

JD-5037 - Drug Profile

JKB-119 - Drug Profile

JKB-121 - Drug Profile

linagliptin - Drug Profile

LJN-452 - Drug Profile

MAT-8800 - Drug Profile

MGL-3196 - Drug Profile

MGL-3745 - Drug Profile

MP-301 - Drug Profile

MSDC-0602 - Drug Profile

MT-2002 - Drug Profile

NC-101 - Drug Profile

NC-2400 - Drug Profile

ND-630 - Drug Profile

ND-654 - Drug Profile

ND-L02s0201 - Drug Profile

NDI-010976 - Drug Profile

NGM-282 - Drug Profile

NGM-313 - Drug Profile

NGM-386 - Drug Profile

NGM-395 - Drug Profile

NP-201 Program - Drug Profile

obeticholic acid - Drug Profile

PBI-4050 - Drug Profile

pentamidine isethionate - Drug Profile

PXS-4728A - Drug Profile

PXS-5033A - Drug Profile

PZ-235 - Drug Profile

remogliflozin etabonate - Drug Profile

RNAi Oligonucleotides for NASH, Cardiovascular and Metabolic Disorders - Drug Profile

RTU-1096 - Drug Profile

RYI-018 - Drug Profile

saroglitazar - Drug Profile

selonsertib - Drug Profile

selonsertib + simtuzumab - Drug Profile

simtuzumab - Drug Profile

Small Molecule for Non-Alcoholic Steatohepatitis - Drug Profile

Small Molecule for Non-Alcoholic Steatohepatitis and Non-Alcoholic Fatty Liver Disease - Drug Profile

Small Molecule to Agonize FXR for NASH and Liver Fibrosis - Drug Profile

Small Molecule to Inhibit DGAT-2 for Dyslipidemia and Non-Alcoholic Steatohepatitis - Drug Profile

Small Molecule to Inhibit SCD-1 for Non-alcoholic Steatohepatitis - Drug Profile

Small Molecules to Activate AMPK for Fatty Liver Disease - Drug Profile

Small Molecules to Antagonize Integrin for Non-Alcoholic Steatohepatitis - Drug Profile

Small Molecules to Antagonize RORC for Immunology, Multiple Sclerosis and Non-Alcoholic Steatohepatitis - Drug Profile

Small Molecules to Antagonize RORC for Immunology, Multiple Sclerosis, Non-Alcoholic Steatohepatitis - Drug Profile

Small Molecules to Inhibit MLK3 for Non-Alcoholic Steatohepatitis - Drug Profile

Small Molecules to Inhibit NLRP3 for Liver Cirrhosis and Non-Alcoholic Steatohepatitis - Drug Profile

solithromycin - Drug Profile

SPL-891.1 - Drug Profile

SR-9238 - Drug Profile

STNM-09 - Drug Profile

TEV-45478 - Drug Profile

TGFTX-3 - Drug Profile

tipelukast - Drug Profile

TRX-318 - Drug Profile

VB-201 - Drug Profile

VB-703 - Drug Profile

VBY-376 - Drug Profile

VK-2809 - Drug Profile

volixibat potassium - Drug Profile

ZGN-839 - Drug Profile

Non-Alcoholic Steatohepatitis - Dormant Projects

Non-Alcoholic Steatohepatitis - Discontinued Products

Non-Alcoholic Steatohepatitis - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Number of Products under Development for Non-Alcoholic Steatohepatitis, H2 2016

Number of Products under Development for Non-Alcoholic Steatohepatitis - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Development by Companies, H2 2016 (Contd..1)

Number of Products under Development by Companies, H2 2016 (Contd..2)

Number of Products under Development by Companies, H2 2016 (Contd..3)

Number of Products under Development by Companies, H2 2016 (Contd..4)

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Development, H2 2016

Comparative Analysis by Unknown Stage Development, H2 2016

Products under Development by Companies, H2 2016

Products under Development by Companies, H2 2016 (Contd..1)

Products under Development by Companies, H2 2016 (Contd..2)

Products under Development by Companies, H2 2016 (Contd..3)

Products under Development by Companies, H2 2016 (Contd..4)

Products under Development by Companies, H2 2016 (Contd..5)

Products under Investigation by Universities/Institutes, H2 2016

Non-Alcoholic Steatohepatitis - Pipeline by Akarna Therapeutics Ltd., H2 2016

Non-Alcoholic Steatohepatitis - Pipeline by AlbireoPharma, H2 2016

Non-Alcoholic Steatohepatitis - Pipeline by Alnylam Pharmaceuticals, Inc., H2 2016

Non-Alcoholic Steatohepatitis - Pipeline by Amunix Operating Inc. , H2 2016

Non-Alcoholic Steatohepatitis - Pipeline by Aquinox Pharmaceuticals Inc., H2 2016

Non-Alcoholic Steatohepatitis - Pipeline by Arisaph Pharmaceuticals, Inc., H2 2016

Non-Alcoholic Steatohepatitis - Pipeline by AstraZeneca Plc, H2 2016

Non-Alcoholic Steatohepatitis - Pipeline by BiOrion Technologies B.V., H2 2016

Non-Alcoholic Steatohepatitis - Pipeline by Bird Rock Bio, Inc., H2 2016

Non-Alcoholic Steatohepatitis - Pipeline by Boehringer Ingelheim GmbH, H2 2016

Non-Alcoholic Steatohepatitis - Pipeline by Bristol-Myers Squibb Company, H2 2016

Non-Alcoholic Steatohepatitis - Pipeline by Can-Fite BioPharma Ltd., H2 2016

Non-Alcoholic Steatohepatitis - Pipeline by Cardax Pharmaceuticals, Inc., H2 2016

Non-Alcoholic Steatohepatitis - Pipeline by Catabasis Pharmaceuticals, Inc., H2 2016

Non-Alcoholic Steatohepatitis - Pipeline by Cerenis Therapeutics Holding SA, H2 2016

Non-Alcoholic Steatohepatitis - Pipeline by Conatus Pharmaceuticals Inc., H2 2016

Non-Alcoholic Steatohepatitis - Pipeline by Connexios Life Sciences Pvt. Ltd., H2 2016

Non-Alcoholic Steatohepatitis - Pipeline by Daiichi Sankyo Company, Limited, H2 2016

Non-Alcoholic Steatohepatitis - Pipeline by DURECT Corporation, H2 2016

Non-Alcoholic Steatohepatitis - Pipeline by Dynavax Technologies Corporation, H2 2016

Non-Alcoholic Steatohepatitis - Pipeline by Eli Lilly and Company, H2 2016

Non-Alcoholic Steatohepatitis - Pipeline by Enanta Pharmaceuticals, Inc., H2 2016

Non-Alcoholic Steatohepatitis - Pipeline by Exicure, Inc., H2 2016

Non-Alcoholic Steatohepatitis - Pipeline by Galectin Therapeutics, Inc., H2 2016

Non-Alcoholic Steatohepatitis - Pipeline by Galmed Pharmaceuticals Ltd., H2 2016

Non-Alcoholic Steatohepatitis - Pipeline by Genextra S.p.a., H2 2016

Non-Alcoholic Steatohepatitis - Pipeline by Genfit SA, H2 2016

Non-Alcoholic Steatohepatitis - Pipeline by GenKyoTex S.A., H2 2016

Non-Alcoholic Steatohepatitis - Pipeline by Gilead Sciences, Inc., H2 2016

Non-Alcoholic Steatohepatitis - Pipeline by GRI Bio, Inc., H2 2016

Non-Alcoholic Steatohepatitis - Pipeline by iCo Therapeutics Inc., H2 2016

Non-Alcoholic Steatohepatitis - Pipeline by Immuron Limited, H2 2016

Non-Alcoholic Steatohepatitis - Pipeline by Inventiva, H2 2016

Non-Alcoholic Steatohepatitis - Pipeline by Ionis Pharmaceuticals, Inc., H2 2016

Non-Alcoholic Steatohepatitis - Pipeline by Ixchel Pharma, LLC, H2 2016

Non-Alcoholic Steatohepatitis - Pipeline by Jenrin Discovery, Inc., H2 2016

Non-Alcoholic Steatohepatitis - Pipeline by Kissei Pharmaceutical Co., Ltd., H2 2016

Non-Alcoholic Steatohepatitis - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2016

Non-Alcoholic Steatohepatitis - Pipeline by Matinas BioPharma Holdings, Inc. , H2 2016

Non-Alcoholic Steatohepatitis - Pipeline by Merck & Co., Inc., H2 2016

Non-Alcoholic Steatohepatitis - Pipeline by Mitochon Pharmaceuticals, Inc., H2 2016

Non-Alcoholic Steatohepatitis - Pipeline by Naia Limited, H2 2016

Non-Alcoholic Steatohepatitis - Pipeline by NGM Biopharmaceuticals, Inc., H2 2016

Non-Alcoholic Steatohepatitis - Pipeline by Nimbus Therapeutics, LLC, H2 2016

Non-Alcoholic Steatohepatitis - Pipeline by Nippon Chemiphar Co., Ltd., H2 2016

Non-Alcoholic Steatohepatitis - Pipeline by Nitto Denko Corporation, H2 2016

Non-Alcoholic Steatohepatitis - Pipeline by Novartis AG, H2 2016

Non-Alcoholic Steatohepatitis - Pipeline by NovaTarg Therapeutics, Inc, H2 2016

Non-Alcoholic Steatohepatitis - Pipeline by Nuevolution AB, H2 2016

Non-Alcoholic Steatohepatitis - Pipeline by Pharmaxis Limited, H2 2016

Non-Alcoholic Steatohepatitis - Pipeline by Promethera Biosciences S.A., H2 2016

Non-Alcoholic Steatohepatitis - Pipeline by ProMetic Life Sciences Inc., H2 2016

Non-Alcoholic Steatohepatitis - Pipeline by Protalix BioTherapeutics, Inc., H2 2016

Non-Alcoholic Steatohepatitis - Pipeline by Saje Pharma, LLC, H2 2016

Non-Alcoholic Steatohepatitis - Pipeline by Shire Plc, H2 2016

Non-Alcoholic Steatohepatitis - Pipeline by Stelic Institute & Co., Inc., H2 2016

Non-Alcoholic Steatohepatitis - Pipeline by Sucampo Pharmaceuticals, Inc., H2 2016

Non-Alcoholic Steatohepatitis - Pipeline by TaiwanJ Pharmaceuticals Co., Ltd., H2 2016

Non-Alcoholic Steatohepatitis - Pipeline by Teva Pharmaceutical Industries Ltd., H2 2016

Non-Alcoholic Steatohepatitis - Pipeline by Therapix Biosciences Ltd, H2 2016

Non-Alcoholic Steatohepatitis - Pipeline by Tobira Therapeutics, Inc., H2 2016

Non-Alcoholic Steatohepatitis - Pipeline by Vascular Biogenics Ltd., H2 2016

Non-Alcoholic Steatohepatitis - Pipeline by Verlyx Pharma Inc., H2 2016

Non-Alcoholic Steatohepatitis - Pipeline by Viking Therapeutics, Inc., H2 2016

Non-Alcoholic Steatohepatitis - Pipeline by Virobay Inc., H2 2016

Non-Alcoholic Steatohepatitis - Pipeline by Zafgen Inc., H2 2016

Non-Alcoholic Steatohepatitis - Pipeline by Zydus Cadila Healthcare Limited, H2 2016

Assessment by Monotherapy Products, H2 2016

Assessment by Combination Products, H2 2016

Number of Products by Stage and Target, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Non-Alcoholic Steatohepatitis - Dormant Projects, H2 2016

Non-Alcoholic Steatohepatitis - Dormant Projects (Contd..1), H2 2016

Non-Alcoholic Steatohepatitis - Dormant Projects (Contd..2), H2 2016

Non-Alcoholic Steatohepatitis - Discontinued Products, H2 2016 330List of Figures

Number of Products under Development for Non-Alcoholic Steatohepatitis, H2 2016

Number of Products under Development for Non-Alcoholic Steatohepatitis - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy Products, H2 2016

Assessment by Combination Products, H2 2016

Number of Products by Top 10 Targets, H2 2016

Number of Products by Stage and Top 10 Targets, H2 2016

Number of Products by Top 10 Mechanism of Actions, H2 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Top 10 Molecule Types, H2 2016

Number of Products by Stage and Top 10 Molecule Types, H2 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
Akarna Therapeutics Ltd.
AlbireoPharma
Alnylam Pharmaceuticals, Inc.
Amunix Operating Inc.
Aquinox Pharmaceuticals Inc.
Arisaph Pharmaceuticals, Inc.
AstraZeneca Plc
BiOrion Technologies B.V.
Bird Rock Bio, Inc.
Boehringer Ingelheim GmbH
Bristol
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll